BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31828167)

  • 1. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
    Mekuria AN; Ayele Y; Tola A; Mishore KM
    J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
    Wu Y; Liu HB; Shi XF; Song Y
    PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
    Yu O; Azoulay L; Yin H; Filion KB; Suissa S
    Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
    Tian J; Liang Y; Qu P
    Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N; Muratov S; Levine M
    Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Yao L; Liu M; Huang Y; Wu K; Huang X; Zhao Y; He W; Zhang R
    Dis Markers; 2019; 2019():6230162. PubMed ID: 30881522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
    Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
    Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis.
    Nie Z; Zhu H; Gu M
    Pharm Biol; 2016 Nov; 54(11):2636-2642. PubMed ID: 27159666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.
    Noto H; Goto A; Tsujimoto T; Noda M
    PLoS One; 2012; 7(3):e33411. PubMed ID: 22448244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials.
    He K; Guo Q; Ge J; Li J; Li C; Jing Z
    J Clin Pharm Ther; 2022 Feb; 47(2):168-177. PubMed ID: 34363237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
    Nie SP; Chen H; Zhuang MQ; Lu M
    Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.